Reshma Kewalramani, is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020.
[6] She graduated in 1998 from the seven-year liberal arts/medical education program at Boston University,[7] Phi Beta Kappa, Summa Cum Laude.
[8] She then entered the biopharma sector, working for Amgen for over 12 years, where she held leadership positions in research and development.
[11] Since she became CEO, Vertex has developed cystic fibrosis therapy drug Trikafta,[12] APOL1-mediated kidney disease experimental apolipoprotein L1 inhibitor, VX-147,[13][14] and pain programs into the clinic.
[15] The company has also partnered with CRISPR Therapeutics to develop gene-editing therapies for the treatment of sickle cell disease and beta thalassemia.